Steven Rabinowe, MD
Endocrinology, Diabetes & Metabolism · Racine, WINPI 1386759389
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $304,630 of the $344,020 with a category attached, or 88.5%. 26 manufacturers reported payments, led by Lilly USA, LLC at 40.0% of the total. Reporting peaked in 2019 at $153,107 and has fallen 90.8% since, to $14,119 in 2024. Among endocrinology, diabetes & metabolism clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,113 payments — averaging $309.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$138K
- Boehringer Ingelheim$52K
- Novo Nordisk$52K
- Johnson & Johnson$27K
- Merck$26K
- AstraZeneca$24K
- plus $26K from 20 others
What the payments were for
- Consulting fees$16,5955%
- Speaking & faculty fees$304,63089%
- Travel & lodging$8,0532%
- Food & beverage$14,7384%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 249 | $137,734 |
| Boehringer Ingelheim | 158 | $51,828 |
| Novo Nordisk | 266 | $51,747 |
| Johnson & Johnson | 36 | $26,755 |
| Merck | 67 | $25,863 |
| AstraZeneca | 98 | $23,602 |
| Bayer | 24 | $13,501 |
| Sanofi-aventis U.S. LLC | 39 | $5,705 |
| Amgen(2 entities) | 21 | $4,777 |
| Dexcom, Inc. | 69 | $999 |
| AbbVie | 26 | $420 |
| IBSA Pharma Inc. | 16 | $270 |
| Amneal Pharmaceuticals LLC | 9 | $146 |
| Medtronic | 2 | $134 |
| Amarin Pharma, Inc. | 6 | $110 |
| Corcept Therapeutics | 6 | $95 |
| Abbott | 5 | $77 |
| Tandem Diabetes Care, Inc. | 3 | $56 |
| Shire North American Group Inc | 3 | $51 |
| Novartis | 2 | $38 |
| Mannkind Corporation | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Antares Pharma, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$344,020 in reported general payments places this provider in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 175 | $256,060 |
| TrulicityDulaglutide | 101 | $148,961 |
| OzempicSemaglutide | 100 | $141,813 |
| RybelsusSemaglutide | 29 | $67,820 |
| JanuviaSitagliptin Phosphate | 41 | $55,327 |
| FarxigaDapagliflozin Propanediol | 38 | $44,488 |
| MounjaroTirzepatide | 20 | $37,225 |
| InvokanaCanagliflozin | 22 | $34,710 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $32,539 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $28,681 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $26,158 |
| TradjentaLinagliptin | 18 | $25,681 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 125 | $24,916 |
| Humalog Kwikpen U-100Insulin Lispro | 59 | $24,090 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $18,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $51,828 | $297,439207 claims |
| Novo NordiskOzempic, Rybelsus | $51,747 | $209,633129 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $137,734 | $190,478134 claims |
| MerckJanuvia, Janumet, Janumet Xr | $25,863 | $95,06474 claims |
| AstraZenecaFarxiga | $23,602 | $44,48838 claims |
| Johnson & JohnsonInvokana | $26,755 | $34,71022 claims |
| AbbVieSynthroid | $420 | $9,987115 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $146 | $3,103184 claims |
| Sanofi-aventis U.S. LLCLantus | $5,705 | $2,71413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Racine
- Aron AdkinsEau Claire$349K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
- Vinay PatelNeenah$64K
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
- Adriana IoachimescuMilwaukee$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.